Skip to main content

Targeted strategies for prevention and treatment of fibrosis-associated liver cancer

Project description

Improving outcome of patients with advanced liver disease

The ERC-funded FIBCAN project will research innovative solutions for fibrosis and liver cancer, which is one of the deadliest in the world. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and almost always results in advanced liver fibrosis. In this context, FIBCAN will identify urgently needed targets for prevention and treatment of fibrosis-driven liver cancer. Specifically, it will investigate Claudin-1 as a target for prevention and treatment of fibrosis-driven HCC. Studies show a connection between Claudin-1 and liver fibrosis and hepatocarcinogenesis as well as overall and liver-specific patient death. The project expects to deliver novel therapeutic strategies for further clinical development.

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 2 125 000,00
Address
Rue De Tolbiac 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 2 125 000,00

Beneficiaries (2)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Net EU contribution
€ 2 125 000,00
Address
Rue De Tolbiac 101
75654 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 2 125 000,00
THE UNIVERSITY OF TEXAS SYSTEM
United States
Net EU contribution
€ 305 000,00
Address
Colorado Street 601
78701 2982 Austin

See on map

Activity type
Higher or Secondary Education Establishments
Other funding
€ 305 000,00